Life Detection Technologies, Inc.

Life Detection Technologies, Inc. develops advanced machine learning solutions for chronic care management, primarily targeting Chronic Obstructive Pulmonary Disease (COPD) with its innovative monitoring technology. Founded in 2014 and headquartered in Sunnyvale, US, Life Detection Technologies, Inc. focuses on innovative solutions for chronic disease management.

The company has completed 3 deals to date, with its most recent being a Seed round on June 24, 2020, raising USD 0. 15 million, bringing the total funds raised to USD 0. 15 million. Eric Howie serves as both the founder and CEO, guiding the company's strategic direction in healthcare technology.

Life Detection Technologies (LDT) specializes in machine learning and data science solutions aimed at enhancing chronic care management, specifically focusing on Chronic Obstructive Pulmonary Disease (COPD). Their flagship product, Detect-Ex, represents the largest longitudinal study of COPD exacerbations, utilizing a passive monitoring system to collect longitudinal patient data. This data is instrumental in refining AI algorithms that predict COPD exacerbations several days in advance, enabling earlier and more precise interventions. LDT's offerings cater primarily to healthcare providers and clinicians managing chronic conditions, with an expanding client base that may include hospitals and outpatient care facilities across various geographical markets, including North America and Europe.

Additionally, the technology developed by LDT is projected to extend beyond COPD to encompass other chronic conditions such as Congestive Heart Failure (CHF) and early Sepsis detection. The revenue model for Life Detection Technologies primarily revolves around partnerships and B2B transactions with healthcare providers and institutions. These partnerships involve subscription-based agreements or service contracts that allow clients to access LDT's innovative monitoring technology and predictive analytics. Through these agreements, healthcare providers can leverage LDT’s technology to enhance patient management strategies effectively.

Specific pricing plans for the services offered by LDT have not been disclosed; however, the business structure implies a recurring revenue stream as healthcare organizations implement LDT’s solutions to improve patient outcomes. The focus on products like Detect-Ex positions the company to capitalize on the growing demand for data-driven healthcare solutions, fostering a sustainable business model centered on chronic disease management. Life Detection Technologies plans to leverage recent Seed funding of USD 0. 15 million raised on June 24, 2020, to support its growth strategies.

The company is focused on expanding its product line, particularly with developments aimed at enhancing capabilities for COPD management and exploring applications for other chronic conditions, including Congestive Heart Failure and early Sepsis detection. Future market expansion efforts are expected to target both North American and European regions, aiming to establish a broader client base by the end of 2021.